title: Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
abstract: Peptide receptor radionuclide therapy (PRRT) has been a well-accepted and effective therapeutic modality for inoperable or metastatic gastroenteropancreatic, bronchopulmonary and other neuroendocrine tumors for almost 2 decades. In general, PRRT is well tolerated with moderate toxicity in the majority of patients if the necessary precautions, appropriate dosage and coadministration of amino acids are undertaken. The two most commonly used radiopeptides, (90)Y-octreotide and (177)Lu-octreotate, produce significant objective response rates, with impact on progression-free survival and overall survival. In addition, biochemical and symptomatic responses are commonly observed. A key issue is the need to establish randomized controlled trials to standardize the treatment and facilitate comparison with other therapeutic strategies available.
authors: Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy.
authors: Lisa
authors: L
authors: Bodei
authors: Mark
authors: M
authors: Kidd
authors: Vikas
authors: V
authors: Prasad
authors: Irvin M
authors: IM
authors: Modlin
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000378:metabolism*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D015282:Octreotide